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PERSPECTIVA
Ethical and epidemiological dilemmas in the treatment of dogs for 
visceral leishmaniasis in Latin America
Bruno L. Travi
Departments of Internal Medicine-Infectious Diseases & Microbiology and Immunology, 
University of Texas Medical Branch, Galveston, Texas, USA
In the Americas there are between 4,500 and 6,800 annual cases of severe visceral leishmaniasis, and 
mortality is estimated to range between 7 and 10%. However, underreporting and subclinical infections 
mask the real epidemiological importance of visceral leishmaniasis. Control efforts, which have typically 
focused on insecticide spraying of sand fly vectors and dog culling, have yielded disparate results. 
Nevertheless, thousands of dogs are sacrificed each year in countries endemic for visceral leishmaniasis. 
Additionally, current guidelines of leishmaniasis control programs have banned dog treatment with drugs 
of human use while therapy with other drugs resulted in high rates of relapses. Society requires that 
control programs take a more humanitarian approach aimed at limiting dog culling. There is an urgent 
need to promote responsible dog-ownership and support research on: a) novel veterinary therapies, b) 
low-cost molecular diagnosis of canine visceral leishmaniasis, and c) determination of dog infectivity 
threshold for proper reservoir management.
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Dilema ético y epidemiológico sobre el tratamiento de perros para la leishmaniasis visceral en 
América Latina 
En las Américas hay entre 4.500 y 6.800 casos anuales de leishmaniasis visceral grave y se estima 
que la mortalidad varía entre 7 y 10 %. Sin embargo, el subregistro y las infecciones subclínicas 
enmascaran la importancia epidemiológica real de la leishmaniasis visceral. Los esfuerzos de control 
que típicamente se han enfocado en la aspersión de insecticidas contra los flebotomíneos vectores 
y el sacrificio de perros, han arrojado resultados dispares. No obstante, miles de perros se sacrifican 
cada año en países endémicos para leishmaniasis visceral. Además, los lineamientos actuales de los 
programas de control de la leishmaniasis han prohibido el tratamiento de perros con medicamentos de 
uso humano, mientras que otras drogas resultan en altas tasas de recaída. La sociedad requiere que 
los programas de control tengan un manejo más humanitario enfocado a limitar el sacrificio canino. Hay 
una necesidad urgente de promover la tenencia responsable de los perros y apoyar la investigación en: 
a) terapias veterinarias novedosas, b) diagnósticos moleculares de bajo costo y c) determinación de 
los umbrales de capacidad infecciosa canina para el manejo adecuado del reservorio.
Palabras clave: leishmaniasis visceral/prevención & control, Leishmania infantum, tratamiento, perros, 
América Latina.
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Zoonotic visceral leishmaniasis caused by 
Leishmania infantum (= L. chagasi in Latin 
America) affects human populations in both the Old 
and New World with varied morbidity and mortality 
rates depending on the socio-economic level of 
the country. In the Americas there are between 
4,500 and 6,800 annual cases of full blown visceral 
leishmaniasis, and mortality is estimated to range 
between 7 and 10% (1). However, underreporting 
and subclinical infections tend to mask the real 
epidemiological importance of this parasitic 
disease in Latin America. Like many other vector-
borne zoonotic diseases, spilling over of infection 
to human populations is linked to multiple social 
and economic factors that put humans in frequent 
contact with disease vectors. In the particular case 
of visceral leishmaniasis, the natural forest cycle of 
transmission between wild mammals and sand fly 
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vectors has gradually shifted from enzootic to peri-
urban and urban transmission. Vector adaptation 
to urban environments and migration of humans to 
the periphery of cities are considered the principal 
reasons for this epidemiological change in which 
dogs have become the main reservoir host (2).
Diverse and even opposing conclusions have been 
reported on the epidemiological impact that control 
efforts have had in regions where L. infantum is 
the etiological agent (2,3). In Latin America, Brazil 
has pioneered the implementation of visceral 
leishmaniasis control, targeting both the sand fly 
vector by means of insecticide spraying and the 
canine population through dog culling (4). The 
fact that control efforts focused on vectors and 
reservoirs have yielded disparate results points 
to the existence of multiple additional factors that 
have influenced intervention outcomes. Not only 
have control measures failed in many regions in 
which transmission is historically endemic, but 
ineffective control has also allowed the geographical 
expansion to newer areas of Southern Brazil and 
other South American countries (Paraguay and 
Argentina) (4,5).
A series of reasons why dog culling was 
less effective than expected to curb visceral 
leishmaniasis transmission has been proposed. A 
variety of serological methods has been used to 
identify infected dogs yet an ill-defined proportion 
of seronegative dogs could still be infected with 
L. infantum as determined by molecular methods 
(6). The prolonged lapse between diagnosis 
and actual culling of dogs was considered to be 
another factor that negatively impacted control 
efforts (3). In resource-limited villages of Brazil 
endemic for visceral leishmaniasis, which were 
characterized by a lack of responsible dog-
ownership, the high rate of dog culling (60.9% 
in two years, not all related to canine visceral 
leishmaniasis) did not translate to reduction in 
canine visceral leishmaniasis incidence, which 
was attributed to the rapid replacement of infected 
dogs with susceptible puppies (7). On the other 
hand, the potential spillover of L. infantum from 
rural (forested) to periurban/urban environments 
represents a continuous influx of parasites to 
uninfected canine populations that remain after 
removal of infected dogs (2). Less frequent 
mechanisms of infection such as sexual and 
transplacental transmission also could contribute 
to sustained L. infantum circulation in the absence 
of sand fly vectors (8,9).
As mentioned before, control programs in 
developing countries focus on dog culling 
regardless of its varied efficacy, and only health 
authorities of developed countries consider that 
dogs should be treated. For example, between 
2005 and 2010, almost 60,000 dogs were sacrificed 
as part of the canine visceral leishmaniasis control 
campaign in the city of Belo Horizonte, Brazil (2). 
Therefore, a positive serology in Latin America 
is equivalent to issuing a “death certificate” 
when dog owners act in accordance with public 
health recommendations. Current guidelines of 
leishmaniasis control programs in South America 
recommend sacrificing any infected dog and 
have banned treatment with drugs of human use 
(10-12). The latter recommendation is based on 
the poor clinical and parasitological results of 
antileishmanial therapy in dogs and the possibility 
that parasites could develop resistance by 
exposure to drugs that are used for patients. In 
fact, strains of L. infantum isolated from treated 
dogs demonstrated more resistance to pentavalent 
antimonials compared with the corresponding pre-
treatment isolates (13). However, because dog 
sacrifice is not mandatory, many owners decide 
to keep their animals and according to their 
economic capabilities initiate the antileishmanial 
treatment. Anecdotal information suggests that 
dogs of affluent families may receive treatment 
with meglumine antimoniate which is still widely 
used to treat patients suffering from cutaneous or 
visceral leishmaniasis.
The social and epidemiological aspects of 
canine visceral leishmaniasis
According to phylogenetic analysis, dogs originated 
from wolves more than 100,000 years ago and 
domestication occurred 15,000-10,000 BCE 
(14,15). From that time on, dogs were increasingly 
integrated into societies, and although some of the 
human-dog interactions are based on utilitarian 
motives (guardian, hunting, cattle ranching, illicit-
drug detection, etc.), companionship is the reason 
for the vast majority of interactions (16). Increasing 
educational level of the owner is associated with 
dogs playing a companion role, which is promoted 
by anthropomorphism (dogs being considered 
more as a person than animal) rather than being 
regarded as a “pet to be owned”. Interestingly, 
dog companionship in less educated people 
is characterized by a lesser tendency toward 
anthropomorphism and allowing dogs to move freely 
in the household with little restrictions (owners set 
few boundaries) (16).
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The combination of the aforementioned human-dog 
interactions has different implications in an urban 
area where visceral leishmaniasis is endemic. On 
one hand, due to canine anthropomorphism there 
is an increasing societal pressure to find alternate 
solutions to euthanasia of infected companion dogs 
by seeking efficacious antileishmanial treatment. 
On the other hand, persons who do not establish 
boundaries most likely allow dogs to roam freely 
in suburban areas, complicating canine visceral 
leishmaniasis control. Several studies (mostly in 
the USA) have estimated that the home-range 
of free-roaming dogs varies between 1 and 10 
hectares (2.5 and 25 acres), but could be larger 
depending on food availability (17). In areas 
endemic for visceral leishmaniasis, this behavior 
could put stray dogs in contact with different sand 
fly populations, increasing the chances of acquiring 
and dispersing L. infantum. A survey carried out 
in different sections of the city of Santiago, Chile 
(not endemic for visceral leishmaniasis), showed 
that 52.4% of unattended street dogs had owners, 
21.9% were actual stray dogs and 8.9% were 
“protected-stray dogs” always living in the same 
vicinity and fed by neighbors (18). Assuming that 
a similar situation occurs in other Latin American 
cities, those results indicate that approximately 
30% of dogs found in the streets are free-roaming 
animals with no health control including canine 
visceral leishmaniasis diagnosis. The importance 
of free-roaming dogs in L. infantum transmission 
was revealed during screenings carried in Posadas 
City, Argentina, at the beginning of an active 
canine visceral leishmaniasis control program. 
A higher infection prevalence was found in stray 
dogs (49%) collected by the Municipal Institute 
of Animal Health compared with 27% infection 
prevalence in dogs screened at households (L. 
Tartaglino, personal communication).
The general public accepts the slaughtering of 
domestic animals for food consumption, while 
the sacrifice of household pets has a different 
connotation. As mentioned before, canines play a 
special societal role and the sole idea of considering 
dog killing as the only alternative to solve a public 
health problem is considered unacceptable in 
most places. However, protecting dogs in canine 
visceral leishmaniasis endemic areas is not an 
easy undertaking. A vaccine showing acceptable 
immunogenicity and protection (≈70%) has recently 
been approved for phase III trial (Leish Tec™, 
Brazil), but still needs to demonstrate high efficacy 
and logistic feasibility before it could be considered 
a sound component of visceral leishmaniasis 
control (19,20). Similarly, despite the fact that 
field trials using deltamethrin-impregnated dog 
collars may be more effective in reducing visceral 
leishmaniasis transmission than dog culling, its 
utilization on a large scale over the course of many 
years makes it difficult to implement (21).
Current status of dog treatment and its 
epidemiological and individual implications
As previously discussed, dogs are at the 
susceptible end of the spectrum of L. infantum 
infection. Progression from the asymptomatic 
to the polysymptomatic stage is characterized 
by an increasing number of signs such as 
lymphadenopathy, dermatitis, onychogryphosis, 
anemia, weight loss, ocular pathologies, hepato-
splenomegaly, diarrhea and kidney dysfunction, 
all of which lead to multi-organ failure and death 
(22). There are several reviews on the treatment 
of canine visceral leishmaniasis (23,24) and thus 
this viewpoint only summarizes the principal 
observations. Only a few of the >120 articles 
regarding dog treatment were controlled studies 
in which infection status before therapy was 
thoroughly evaluated (24). Nevertheless, these 
studies indicated that treatment of canine visceral 
leishmaniasis is cumbersome and characterized 
by high rates of relapses regardless of the 
antileishmanial drugs used, either as a single drug 
or in combination regimens. Long-term follow 
up of treated dogs revealed that true clinical 
and parasitological cure is rarely achieved, and 
underscores the exquisite susceptibility of most 
canines to L. infantum.
Pentavalent antimonials: Meglumine antimoniate 
(Glucantime®) or sodium stibogluconate 
(Pentostam®) have been the first-line drugs to 
treat patients suffering cutaneous or visceral 
leishmaniasis, and these compounds are still used 
in many countries. Glucantime treatment protocols 
are based on the antimony (SbV) concentration 
which is approximately 85 mg/mL. Meglumine 
antimoniate was utilized to treat canine visceral 
leishmaniasis principally in countries of the 
Mediterranean basin (50-150 mg/kg, subcutaneous 
or intramuscular for 3-4 weeks). Initially promising 
results were consistently followed by persistent 
parasites in spleen, bone marrow, liver and lymph 
nodes, including 70-100% clinical relapses at 
one year post-treatment, all of which indicated 




Allopurinol: This drug, which is given primarily to treat 
patients with hyperuricemia that leads to chronic 
gout, is the compound most widely prescribed by 
veterinarians to treat canine visceral leishmaniasis. 
It has been proposed that the antileishmanial 
activity of allopurinol is based on the blockade 
of the purine salvage pathway of amastigotes, 
producing purine starvation and parasite death (26). 
Although in vivo results suggested that allopurinol 
acts as a parasitostatic drug, it is feasible that its 
actual parasiticidal effect is masked by the short 
half-life of the parent drug (2 hours) and lack of 
antileishmanial activity of the major metabolite 
(oxypurinol) (27).The drug has been used at doses 
of 15-30 mg/kg/day per os, divided in two or three 
daily doses over 4 to >12 months (24). This drug 
became well accepted in spite of the marginal 
efficacy because of its low cost and the ease of 
household administration. Nevertheless, it is not 
uncommon that dog owners become discouraged 
with the protracted therapy and incomplete clinical 
and parasitological cure and, therefore, tend to 
abandon the treatment. Consequently, relapses are 
the norm once treatment is suspended (23,24).
Allopurinol combined with pentavalent antimonials: 
The debatable convenience and efficacy of 
allopurinol regimens prompted researchers to 
evaluate its inclusion in combination therapies. The 
co-administration of meglumine antimoniate and 
allopurinol showed initial clinical and parasitological 
remission. The treatments were initiated by 
subcutaneous, intramuscular or intravenous 
administration of meglumine antimoniate (100 mg/
kg for 20-30 days) and oral allopurinol (15 mg/
kg bid) for ≥8 months. These results suggest that 
meglumine antimoniate given at the beginning of 
treatment sharply reduced the parasite burden which 
was then kept at bay by chronic administration of 
allopurinol. Nevertheless, parasite elimination was 
not achieved in spite of clinical remission (23).
More recently, allopurinol was evaluated in 
combination with liposomal meglumine antimoniate 
in naturally infected dogs at different stages of 
clinical canine visceral leishmaniasis. Although 
positive results were obtained compared with 
these drugs used as monotherapy, the weakness 
of the study was the small number of dogs per 
group and the heterogeneity of parasite burden 
between groups before treatment (28). From the 
epidemiological standpoint, there was no clear 
benefit of the combination therapy vs. allopurinol 
alone because reduction of dog infectivity to sand 
fly vectors (xenodiagnoses) at 140 and 200 days 
post-treatment was similar in both groups of dogs. 
Besides, like other therapeutic schemes, allopurinol 
was administered daily for over 4 months, a scheme 
that is likely to affect adherence to treatment. Two 
additional factors that would prevent its large-scale 
implementation in Latin America are the utilization of 
liposomes, which are costly and involve parenteral 
administration, and the use of pentavalent 
antimonials which are banned for veterinary use 
according to public health guidelines (10,12).
Other drugs previously or currently used in humans 
(amphotericin B, pentamidine, miltefosine) have 
shown varying results, usually characterized by 
clinical remission and parasitological persistence 
(23). In conclusion, none of the drugs used so far 
can ensure parasitological cure in spite of clinical 
improvement, and almost all therapeutic regimens 
have a high rate of relapse at different times post-
treatment. As mentioned before, in resource-limited 
countries of Latin America, the drugs commonly 
used to complement allopurinol treatment would 
be costly and not recommended for veterinary use, 
leaving no therapeutic alternative. 
Treatment of canine visceral leishmaniasis can be 
viewed from two different standpoints, i.e., the health 
of the individual animal and the epidemiological 
impact the treatment may have. Most dog owners 
regard clinical cure or remission as the sole goal 
of treatment and this is likely to continue unless 
leishmaniasis control programs can change the 
community’s individualistic view of the problem. 
On the other hand, the epidemiological viewpoint 
considers that interrupting transmission is the key 
result of treatment regardless of the clinical outcome 
of therapy. Assessing clinical improvement of dogs 
is fairly simple, while determining their infectivity 
to sand fly vectors is cumbersome. There is no 
established threshold of tissue parasitism that could 
be reliably associated with infectivity to sand flies 
and, therefore, any parasitologically positive dog is 
considered to be potentially infectious under public 
health guidelines. This assumption may be closer to 
reality in the Old World where sand fly species seem to 
be more efficient vectors than those of Latin America 
(29,30). However, recent studies in Spain indicated 
that treatment, either with allopurinol-meglumine 
antimoniate or any of these drugs as monotherapy, 
significantly reduced dog infectivity to Phlebotomus 
perniciosus (60-67% pre-treatment down to 0-11% 
post-treatment) as determined by xenodiagnosis at 
60 days post-treatment (31). Consequently, it would 
be useful to determine whether in the absence of 
the “magic bullet”, sub-curative treatments in which 
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L. infantum is detected only by DNA amplification 
could be of clinical and epidemiological benefit in 
the American continent where a comparatively less 
efficient vector (L. longipalpis) predominates.
The road to a more efficacious and humane 
control of visceral leishmaniasis
It is imperative to realize that despite current control 
measures, several thousands of dogs are or will 
be infected with L. infantum. Under the present 
circumstances these dogs will die of canine visceral 
leishmaniasis, or will be unsuccessfully treated 
or will be euthanized to eliminate the reservoir 
host. Society requires that dog management in 
Leishmania-endemic areas of Latin America take a 
more humanitarian turn. 
The strategies used so far in Latin America to 
control visceral leishmaniasis include: a) insecticide 
spraying of entire neighborhoods or focusing on 
houses where visceral leishmaniasis patients are 
detected, b) removal of potential sand fly breeding 
sites around houses, c) serological identification 
of infected dogs followed by euthanasia, d) canine 
neutering, and e) intensification of stray dog 
removal. Other complementary measures such 
as community education on visceral leishmaniasis 
prevention and responsible dog ownership only 
recently have begun to be adopted and their long-
term efficacy requires further evaluation (32).
As described in this viewpoint, control measures are 
only partially efficacious and therefore there is an 
urgent need to develop and adopt additional strategies 
that could improve visceral leishmaniasis prevention 
and control. The following approaches, ranging from 
short-term application to mid-term development and 
implementation, should be considered:
a) Mandatory use of delthamethrin-impregnated 
collars on infected dogs would decrease the 
epidemiological risk that these animals represent. 
This strategy would be more feasible than providing 
delthamethrin-impregnated collars to the whole 
canine population of the city over a period of several 
years. Voluntary use of delthamethrin-impregnated 
collars in household pets could also be recommended 
as part of the community education.
b) Community education about visceral leishmaniasis 
could be complemented by dog ownership 
accountability, enforced by implementing sub-
cutaneous microchips that identify free-roaming 
dogs. Since this approach is currently not feasible, 
university research groups in bioengineering and 
government should work together to develop 
low-cost microchips. This tool should be made 
available mostly in urban areas where human and 
dog densities and transmission rates are higher 
compared with rural areas.
c) Field diagnosis of canine visceral leishmaniasis 
relying only on serology will miss an unknown 
proportion of infected dogs. Therefore, in the 
short term, control programs will require the 
development of low-cost molecular amplification 
methods capable of detecting dogs at early stages 
of infection before they become more infectious to 
sand flies. Research should make emphasis on 
isothermal amplification assays, which appear to 
be the next generation of field-applicable diagnostic 
methods. With these tools in place, infected 
stray dogs could be efficiently removed from the 
canine visceral leishmaniasis cycle or subjected 
to treatment provided newer efficacious therapies 
become available.
d) Substantial support should be given to research 
aimed at the identification of new antileishmanial 
molecules specifically developed to treat dogs.
The establishment of canine infectivity thresholds 
using well-designed multidisciplinary studies will 
determine the epidemiological risk, helping health 
authorities in their decision making. The difficulty 
of the latter studies would be compensated by the 
possibility of identifying antileishmanial molecules 
and treatment regimens that in addition to 
seeking animal well-being will fulfill epidemiological 
requirements in Latin America.
Acknowledgments
The critical review of the manuscript by Dr. Peter 
Melby (University of Texas Medical Branch, 
Galveston) is appreciated.
Financial support
Department of Internal Medicine-Infectious Diseases, 
University of Texas Medical Branch.
Conflict of interest
The author has no conflict of interest related to 
this manuscript
References
1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano 
J, et al. Leishmaniasis worldwide and global estimates 
of its incidence. PloS One. 2012;7:e35671. http://dx.doi.
org/10.1371/journal.pone.0035671
2. Harhay MO, Olliaro PL, Costa DL, Costa CH. Urban 




3. Coura-Vital W, Marques MJ, Veloso VM, Roatt BM, 
Aguiar-Soares RD, Reis LE, et al. Prevalence and factors 
associated with Leishmania infantum infection of dogs 
from an urban area of Brazil as identified by molecular 
methods. PLoS Negl Trop Dis. 2011;5:e1291. http://dx.doi.
org/10.1371/journal.pntd.0001291
4. Costa CH. How effective is dog culling in controlling zoonotic 
visceral leishmaniasis? A critical evaluation of the science, 
politics and ethics behind this public health policy. Rev Soc 
Bras Med Trop. 2011;44:232-42. http://dx.doi.org/10.1590/
S0037-86822011005000014
5. Salomon O, Sinagra A, Nevot M, Barberian G, Paulin 
P, Estevez J, et al. First visceral leishmaniasis focus in 
Argentina. Mem Inst Oswaldo Cruz. 2008;103:109-11. http://
dx.doi.org/10.1590/S0074-02762008000100018
6. Mohammadiha A, Haghighi A, Mohebali M, Mahdian R, 
Abadi AR, Zarei Z, et al. Canine visceral leishmaniasis: A 
comparative study of real-time PCR, conventional PCR, and 
direct agglutination on sera for the detection of Leishmania 
infantum infection. Vet Parasitol. 2013;192:83-90. http://
dx.doi.org/10.1016/j.vetpar.2012.10.013
7. Nunes CM, Lima VM, Paula HB, Perri SH, Andrade 
AM, Dias FE, et al. Dog culling and replacement in an 
area endemic for visceral leishmaniasis in Brazil. Vet 
Parasitol. 2008;153:19-23. http://dx.doi.org/10.1016/j.
vetpar.2008.01. 005
8. Silva FL, Oliveira RG, Silva TM, Xavier MN, Nascimento 
EF, Santos RL. Venereal transmission of canine visceral 
leishmaniasis. Vet Parasitol.2009;160:55-9. http://dx.doi.
org/10.1016/j.vetpar.2008.10.079
9. Boggiatto PM, Gibson-Corley KN, Metz K, Gallup 
JM, Hostetter JM, Mullin K, et al. Transplacental 
transmission of Leishmania infantum as a means for 
continued disease incidence in North America. PLoS Negl 
Trop Dis. 2011;5:e1019. http://dx.doi.org/10.1371/journal.
pntd.0001019
10. Honorable Concejo Deliberante de la Ciudad de 
Posadas. Ordenanza número 2.300. Posadas; Concejo 
Deliberante de la Ciudad de Posadas; 2007.
11. Ministério da Saúde. Portaria Interministerial Nº 1.426 
MdS. Brasilia: Ministério da Saúde; 2008.
12. Honorable Concejo Deliberante de la Ciudad de 
Posadas. Ordenanza número 2.451. Posadas; Concejo 
Deliberante de la Ciudad de Posadas; 2007.
13. Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity 
to meglumine antimoniate (glucantime) of Leishmania 
infantum isolated from dogs after several courses of drug-
treatment. Ann Trop Med Parasitol. 1992;86:613-20.
14. Vila C, Savolainen P, Maldonado JE, Amorim IR, Rice 
JE, Honeycutt RL, et al. Multiple and ancient origins of 
the domestic dog. Science. 1997;276:1687-9. http://dx.doi.
org/10.1126/science.276.5319.1687
15. Olsen SJ. Origins of the domestic dog: the fossil record. 
Tucson: University of Arizona Press; 1985.
16. Dotson MJ, Hyatt EM. Understanding dog-human com-
panionship. J Bus Res. 2008;61:457-66.
17. Meek PD. The movement, roaming behaviour and home 
range of free-roaming domestic dogs, Canis lupus familiaris, 
in coastal New South Wales. Wildlife Res. 1999;26:847-55. 
18. Ibarra L, Espinola F, Echeverría M. Una prospección a 
la población de perros existente en las calles de la ciudad 
de Santiago, Chile. Avances en Ciencias Veterinarias. 
2006;21:33-9.
19. Palatnik-de-Sousa CB. Vaccines for canine leishmaniasis. 
Front Immunol. 2012;3:69. http://dx.doi.org/10.3389/fimmu. 
2012.00069
20. Ministério da Agricultura, Pecuária e Abastecimento. 
Ofício Nº 028/CPV/DFIP de 25.01.2013. Brasil: MAPA; 2013.
21. Reithinger R, Coleman PG, Alexander B, Vieira EP, Assis 
G, Davies CR. Are insecticide-impregnated dog collars a 
feasible alternative to dog culling as a strategy for controlling 
canine visceral leishmaniasis in Brazil? Int J Parasitol. 
2004;34:55-62. http://dx.doi.org/10.1016/j.ijpara.2003.09.006
22. Solano-Gallego L, Koutinas A, Miro G, Cardoso L, 
Pennisi MG, Ferrer L, et al. Directions for the diagnosis, 
clinical staging, treatment and prevention of canine 
leishmaniosis. Vet Parasitol. 2009;165:1-18. http://dx.doi.
org/10.1016/j.vetpar.2009.05.022
23. Baneth G, Shaw SE. Chemotherapy of canine leishmaniosis. 
Vet Parasitol. 2002;106:315-24. http://dx.doi.org/10.1016/
S0304-4017(02)00115-2
24. Noli C, Auxilia ST. Treatment of canine Old World visceral 
leishmaniasis: A systematic review. Vet Dermatol. 2005;16:213-
32. http://dx.doi.org/10.1111/j.1365-3164.2005.00460.x
25. Ikeda-Garcia FA, Lopes RS, Marques FJ, de Lima 
VMF, Morinishi CK, Bonello FL, et al. Clinical and 
parasitological evaluation of dogs naturally infected by 
Leishmania (Leishmania) chagasi submitted to treatment 
with meglumine antimoniate. Vet Parasitol.2007;143:254-9. 
http://dx.doi.org/10.1016/j.vetpar.2006.08.019
26. Balana-Fouce R, Reguera RM, Cubria JC, Ordoñez D. The 
pharmacology of leishmaniasis. Gen Pharmacol. 1998;30: 
435-43. http://dx.doi.org/10.1016/S0306-3623(97)00268-1
27. Maddison JE, Page SW, Church D. Small animal clinical 
pharmacology. London: Saunders Limited; 2008.
28. da Silva SM, Amorim IF, Ribeiro RR, Azevedo EG, 
Demicheli C, Melo MN, et al. Efficacy of combined therapy 
with liposome-encapsulated meglumine antimoniate and 
allopurinol in treatment of canine visceral leishmaniasis. 
Antimicrob Agents Chemother. 2012;56:2858-67. http://
dx.doi.org/10.1128/AAC.00208-12
29. Molina R, Amela C, Nieto J, San-Andres M, Gonzalez F, 
Castillo JA, et al. Infectivity of dogs naturally infected with 
Leishmania infantum to colonized Phlebotomus perniciosus. 
Trans R Soc Trop Med Hyg. 1994;88:491-3. 
30. Travi BL, Tabares CJ, Cadena H, Ferro C, Osorio Y. 
Canine visceral leishmaniasis in Colombia: Relationship 
between clinical and parasitologic status and infectivity for 
sand flies. Am J Trop Med Hyg. 2001;64:119-24. 
31. Miro G, Galvez R, Fraile C, Descalzo MA, Molina R. Infectivity 
to Phlebotomus perniciosus of dogs naturally parasitized 
with Leishmania infantum after different treatments. Parasit 
Vectors.2011;4:52. http://dx.doi.org/10.1186/1756-3305-4-52
32. Esch KJ, Pontes NN, Arruda P, O’Connor A, Morais L, 
Jeronimo SM, et al. Preventing zoonotic canine leishmaniasis 
in northeastern Brazil: Pet attachment and adoption of 
community Leishmania prevention. Am J Trop Med Hyg. 
2012;87:822-31. http://dx.doi.org/10.4269/ajtmh.2012.12-0251
